Roche Paying $390m Up Front For Fibrosis-Fighting Promedior

The deal, which includes up to $1bn for milestones, gives Roche Promedior’s PRM-151, a Phase III-ready asset for IPF that has also completed a Phase II study in myelofibrosis and could be effective in a broad range of fibrotic diseases.

SC1911_Aquisition_377287183_1200.jpg
Roche will pay $390m initially and up to $1bn in milestone fees. • Source: Shutterstock

After Bristol-Myers Squibb Co. declined to exercise its option to buy Promedior Inc. in mid-2018, the small biopharmaceutical company began to consider its options for financing Phase III development of its lead asset PRM-151 in idiopathic pulmonary fibrosis (IPF). Ultimately, Promedior opted to be acquired by another big pharma, announcing on 15 November that Roche will pay $390m up front and up to $1bn in development, regulatory and commercial milestone fees.

CEO and Lightstone Ventures general partner Jason Lettman told Scrip that Promedior has had an eventful year since the presentation...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.